Association Between LRG and Histologic Remission in Ulcerative Colitis - Trial NCT06372613
Access comprehensive clinical trial information for NCT06372613 through Pure Global AI's free database. This phase not specified trial is sponsored by Showa Inan General Hospital and is currently Recruiting. The study focuses on Ulcerative Colitis in Histologic Remission. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Showa Inan General Hospital
Timeline & Enrollment
N/A
Feb 25, 2024
Dec 31, 2025
Primary Outcome
Histologic remission of UC
Summary
We attempt to clarify the serum leucine-rich ฮฑ 2-glycoprotein (LRG) level which can predict
 histologic remission in ulcerative colitis patients in this study. Colonoscopy with histology
 will be performed when histologic remission is predicted, irrespective of symptoms or serum
 LRG values. Serum LRG levels are analyzed by an enzyme-linked immunosorbent assay.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06372613
Non-Device Trial